Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care

Rhea-AI Summary

Roche has completed the acquisition of LumiraDx's Point of Care technology, following all required clearances. This acquisition enhances Roche's diagnostics portfolio with a multi-assay platform that consolidates various tests on a single instrument. The integration aims to expand global access to decentralised diagnostic testing, particularly in primary care and low/middle-income countries.

Key points:

• LumiraDx's technology complements Roche's offerings across multiple disease areas
• The platform allows for future expansion into molecular testing
• Roche will continue partnering with the Bill & Melinda Gates Foundation to develop a rapid point-of-care molecular tuberculosis test
• The acquisition addresses the global need for accessible diagnostics, particularly in underserved areas

Positive

• Expansion of Roche's diagnostics portfolio with LumiraDx's multi-assay point of care platform
• Potential to increase market presence in primary care and low/middle-income countries
• Future expansion possibilities into molecular testing
• Continued partnership with Bill & Melinda Gates Foundation for tuberculosis test development

Negative

• None.

• The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances.
• LumiraDx’s transformative Point of Care solution will complement Roche’s diagnostics portfolio across Clinical Chemistry, Immunochemistry, Coagulation and Molecular, and across multiple disease areas.
• By integrating LumiraDx, Roche will further its ambition to deliver decentralised solutions that expand global access to testing in primary care settings worldwide.

Basel, 29 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the completion of the acquisition of LumiraDx’s Point of Care technology, following the receipt of all required antitrust and regulatory clearances. Roche will now embark on the full integration of the company’s innovative multi-assay point of care platform and the related R&D, operational and commercial sites into its global organisation.

Through this acquisition, Roche complements its diagnostics portfolio with a simple-to-use platform that consolidates a wide range of immunoassay and clinical chemistry tests on a single instrument, with the future potential to expand into molecular testing. The innovative solution will allow Roche to further expand its offering in decentralised patient care, and drive global access to timely and actionable diagnostic results.

“Access to diagnostic testing is critical for the delivery of healthcare worldwide and we are confident that the LumiraDx platform and technology will help us expand the availability of testing, especially in settings such as primary care and low and middle income countries,” said Matt Sause, CEO of Roche Diagnostics.

Veronique Ameye, Chief Executive Officer of LumiraDx, added: “We are absolutely delighted to continue our journey as part of Roche Diagnostics. Being an integral part of the Roche network opens the door to realising the full potential of our Point of Care technology, and to increasing patient access to community-based healthcare around the world. We look forward to writing the next chapter in our shared efforts to deliver even greater impact for patients.”

Roche announced the signing of its agreement to acquire LumiraDx’s Point of Care technology at the end of 2023. 

Continued Partnership with the Bill & Melinda Gates Foundation
As part of the acquisition, Roche will continue to partner with the Bill & Melinda Gates Foundation on the further expansion of the platform’s molecular diagnostic capabilities through the development of an innovative and rapid point of care molecular tuberculosis test. Today, we are still facing an estimated gap of more than 4 million people worldwide whose tuberculosis remains undiagnosed - and as a consequence, untreated.¹ With a lower-cost solution that is ideally suited to providing diagnostics at the point of care in remote settings, this test aims to enable better tuberculosis detection and treatment to achieve global epidemic control targets.

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In recognising our endeavour to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the fifteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] World Health Organization (WHO) Global Tuberculosis Report 2022. Accessed 30 May 2024. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022
 

Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Hans Trees, PhD Phone: +41 79 407 72 58	Sileia Urech Phone: +41 79 935 81 48
Nathalie Altermatt Phone: +41 79 771 05 25	Lorena Corfas Phone: +34 620 29 25 51
Simon Goldsborough Phone: +44 797 32 72 915	Karsten Kleine Phone: +41 79 461 86 83
Nina Mählitz Phone: +41 79 327 54 74	Kirti Pandey Phone: +49 172 6367262
Yvette Petillon Phone: +41 79 961 92 50	Dr Rebekka Schnell Phone: +41 79 205 27 03

Roche Investor Relations

Dr Bruno Eschli Phone: +41 61 68-75284 E-mail: bruno.eschli@roche.com	Dr Sabine Borngräber Phone: +41 61 68-88027 E-mail: sabine.borngraeber@roche.com
Dr Birgit Masjost Phone: +41 61 68-84814 E-mail: birgit.masjost@roche.com

Investor Relations North America

Loren Kalm Phone: +1 650 225 3217 E-mail: kalm.loren@gene.com

Attachment

• 29072024_MR_Roche_LumiraDX_closing_en

FAQ

What is the significance of Roche's acquisition of LumiraDx's Point of Care technology?

The acquisition allows Roche (RHHBY) to expand its diagnostics portfolio, particularly in decentralized patient care. It adds a multi-assay platform that can perform various tests on a single instrument, potentially increasing access to diagnostic testing in primary care settings and low/middle-income countries.

How will the LumiraDx acquisition impact Roche's (RHHBY) market position?

The acquisition is expected to strengthen Roche's position in the point-of-care diagnostics market. It complements Roche's existing portfolio across Clinical Chemistry, Immunochemistry, Coagulation, and Molecular diagnostics, potentially expanding their market reach, especially in primary care settings.

What are the future plans for the LumiraDx platform under Roche (RHHBY)?

Roche plans to fully integrate LumiraDx's platform, R&D, and operations into its global organization. There are plans to expand the platform's capabilities into molecular testing. Additionally, Roche will continue partnering with the Bill & Melinda Gates Foundation to develop a rapid point-of-care molecular tuberculosis test.

How does the LumiraDx acquisition align with Roche's (RHHBY) global healthcare strategy?

The acquisition aligns with Roche's ambition to deliver decentralized diagnostic solutions and expand global access to testing. It particularly focuses on improving diagnostic capabilities in primary care settings worldwide and in low and middle-income countries, addressing the need for timely and actionable diagnostic results.